Proposals made by decision makers in Northern Ireland could see delays for patients needing to start treatment with biologic therapies in accessing these therapies.
Patients in Northern Ireland urged to voice concerns on Health Service Savings Plans
Crohn’s & Colitis UK would like to draw a new consultation on planned savings in 5 Health and Social Care (HSC) Trusts to the attention of people with IBD and their families in Northern Ireland. We believe that some of the proposed savings outlined by the Belfast Health and Social Care Trust in particular could have a seriously negative impact on IBD patients.
The Department of Health (DOH) has asked the Trusts to develop savings plans adding up to £70 million to balance their books for the coming financial year. Following a series of meetings, the plans were published and are open for comment until Thursday 5th October.
The Belfast Health and Social Care Trust Savings Plan, which sets out proposals to deliver savings of £26.3 million, is of particular concern for people with Crohn’s Disease and Ulcerative Colitis. The consultation document outlines a number of savings proposals that “may be considered major and /or controversial” including deferring high-cost treatments for people with IBD until 2018/19 ( biologics and biosimilars) (on p.17 of the document)
The Savings Plan states that “it is recognised that patients’ lives would be adversely impacted by having to live with the conditions without treatment”.
Crohn’s & Colitis UK also recognises that patients being denied the recommended treatments when they are needed most could lead to very poor outcomes including uncontrolled symptoms, unplanned admissions to hospital, emergency surgery and further complications.
This proposal does not affect people already receiving biologic or biosimilar treatments but would apply to new patients.
We in the Northern Ireland IBD community work to ensure that patients receive high quality person centred care wherever they live. The proposal of deferring biological treatment for Inflammatory Bowel Disease on purely cost saving grounds puts this principle at risk.
Crohn’s & Colitis will be responding in full to this consultation and will be working with colleagues from The Northern Ireland IBD Interest Group and other key stakeholders to coordinate this response, highlighting the deep inequity and potentially devastating impacts of these plans.
We would urge anyone directly affected by Crohn’s Disease or Ulcerative Colitis who is concerned about these proposed changes to submit their own response, using the questionnaire in section 6 of the consultation document.
Read our latest news
Catch up on the latest news from Crohn’s & Colitis UK
Helpline Service
Temporary closure - 10/06/2026
Our Helpline will be closed from Wednesday 10 June and will reopen at 10am on Monday 15 June.
We may be closed but we have lots of information here on our website.
If you need urgent medical advice you can call NHS 111 or in Northern Ireland phone your local Phone First. In an emergency call 999 or go to your nearest A&E.
If you need emotional support the Samaritans are available 24 hours a day, 7 days a week on 116 123.
We know it can be difficult to live with, or support someone living with Crohn’s or Colitis. But we’re with you. We can give you the right information and support at the right time.
We’re here for everyone.
How Can We Help?
- We can help you understand Crohn’s and Colitis
- Listen and talk about living with IBD
- Help you connect with others in the Crohn’s and Colitis community
- Give you contact details of specialist organisations
- We can support you to live well with Crohn’s or Colitis and provide up-to-date, evidence-based information
Please be aware we’re not medically or legally trained. We cannot provide detailed financial or benefits advice or specialist emotional support.
Please contact us via telephone, email or LiveChat - 10am to 3pm, Monday to Friday (except English bank holidays).
If you need specific medical advice about your condition, your GP or IBD team will be best placed to help.